Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis

Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological options. The beneficial effects of relaxin peptide treatment were demonstrated in clinically relevant animal models of liver fibrosis. However, the use of relaxin is pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:FASEB J
Hauptverfasser: Kaftanovskaya, Elena M., Ng, Hooi Hooi, Soula, Mariluz, Rivas, Bryan, Myhr, Courtney, Ho, Brian A., Cervantes, Briana A., Shupe, Thomas D., Devarasetty, Mahesh, Hu, Xin, Xu, Xin, Patnaik, Samarjit, Wilson, Kenneth J., Barnaeva, Elena, Ferrer, Marc, Southall, Noel T., Marugan, Juan J., Bishop, Colin E., Agoulnik, Irina U., Agoulnik, Alexander I.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Federation of American Societies for Experimental Biology 2019
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988856/
https://ncbi.nlm.nih.gov/pubmed/31419161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fj.201901046R
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge